DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

ImmunoGen (NASDAQ: IMGN)

8.75 -0.47 (-5.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

IMGN $8.75 -5.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.95
Previous Close $9.22
Daily Range $8.70 - $9.66
52-Week Range $7.70 - $18.19
Market Cap $751.7M
P/E Ratio -11.11
Dividend (Yield) $0.00 (0.0%)
Volume 1,742,670
Average Daily Volume 1,351,090
Current FY EPS -$0.70

Sector

Healthcare

Industry

Drugs

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website: http://www.immunogen.com/

News & Commentary

ImmunoGen, Inc. Pushes Forward

With just $4.2 million in royalties from Roche's Kadcyla, investors need to be focused on ImmunoGen's internal pipeline.

ImmunoGen's (IMGN) CEO Daniel Junius on Q1 2015 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q3 2014 Results - Earnings Call Webcast

ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape

ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape

Immunogen (IMGN) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas: Immunogen (IMGN) Is Today's Strong On High Relative Volume Stock

Today's Weak On High Volume Stock: Immunogen (IMGN)

3 Value Stocks Near 52-Week Lows Worth Buying

These value stocks may be hitting a new 52-week low, but they may not be there for long!

First Week of IMGN November 22nd Options Trading

Breast Cancer Occurs Most Often in These 5 States

Breast cancer was diagnosed in more than 220,000 women in 2011. Find out in which five states a breast cancer diagnosis is the most common, as well as what current and developing therapies are being used to treat this terrible disease.

See More IMGN News...

IMGN's Top Competitors

IMGN $8.75 (-5.10%)
Current stock: IMGN
AMGN $147.26 (0.01%)
Current stock: AMGN
GILD $110.71 (3.29%)
Current stock: GILD
BIIB $321.67 (1.77%)
Current stock: BIIB